nodes	percent_of_prediction	percent_of_DWPC	metapath
Cabergoline—CYP3A4—Calcitriol—psoriasis	0.0203	0.191	CbGbCtD
Cabergoline—CYP3A4—Methoxsalen—psoriasis	0.0158	0.149	CbGbCtD
Cabergoline—CYP3A4—Cholecalciferol—psoriasis	0.0104	0.0986	CbGbCtD
Cabergoline—CYP3A4—Mycophenolate mofetil—psoriasis	0.00905	0.0855	CbGbCtD
Cabergoline—CYP3A4—Triamcinolone—psoriasis	0.00905	0.0855	CbGbCtD
Cabergoline—CYP3A4—Betamethasone—psoriasis	0.00776	0.0733	CbGbCtD
Cabergoline—CYP3A4—Prednisolone—psoriasis	0.00766	0.0724	CbGbCtD
Cabergoline—CYP3A4—Hydrocortisone—psoriasis	0.00726	0.0686	CbGbCtD
Cabergoline—CYP3A4—Prednisone—psoriasis	0.00723	0.0683	CbGbCtD
Cabergoline—CYP3A4—Cyclosporine—psoriasis	0.00686	0.0648	CbGbCtD
Cabergoline—CYP3A4—Dexamethasone—psoriasis	0.00452	0.0427	CbGbCtD
Cabergoline—Paraesthesia—Cyclosporine—psoriasis	0.000552	0.000665	CcSEcCtD
Cabergoline—Shock—Prednisolone—psoriasis	0.00055	0.000663	CcSEcCtD
Cabergoline—Dyspnoea—Cyclosporine—psoriasis	0.000548	0.00066	CcSEcCtD
Cabergoline—Somnolence—Cyclosporine—psoriasis	0.000546	0.000658	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000546	0.000658	CcSEcCtD
Cabergoline—Oedema—Hydrocortisone—psoriasis	0.000546	0.000658	CcSEcCtD
Cabergoline—Asthenia—Mycophenolic acid—psoriasis	0.000545	0.000657	CcSEcCtD
Cabergoline—Hypertension—Triamcinolone—psoriasis	0.000544	0.000655	CcSEcCtD
Cabergoline—Insomnia—Mycophenolate mofetil—psoriasis	0.000542	0.000653	CcSEcCtD
Cabergoline—Dyspepsia—Cyclosporine—psoriasis	0.000541	0.000652	CcSEcCtD
Cabergoline—Hyperhidrosis—Prednisolone—psoriasis	0.000541	0.000651	CcSEcCtD
Cabergoline—Nausea—Hydroxyurea—psoriasis	0.000539	0.000649	CcSEcCtD
Cabergoline—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000538	0.000649	CcSEcCtD
Cabergoline—Pruritus—Mycophenolic acid—psoriasis	0.000538	0.000648	CcSEcCtD
Cabergoline—Shock—Hydrocortisone—psoriasis	0.000537	0.000647	CcSEcCtD
Cabergoline—Pneumonia—Methotrexate—psoriasis	0.000536	0.000645	CcSEcCtD
Cabergoline—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000535	0.000644	CcSEcCtD
Cabergoline—Decreased appetite—Cyclosporine—psoriasis	0.000534	0.000644	CcSEcCtD
Cabergoline—Somnolence—Mycophenolate mofetil—psoriasis	0.000533	0.000642	CcSEcCtD
Cabergoline—Depression—Methotrexate—psoriasis	0.000531	0.00064	CcSEcCtD
Cabergoline—Ill-defined disorder—Dexamethasone—psoriasis	0.000531	0.000639	CcSEcCtD
Cabergoline—Ill-defined disorder—Betamethasone—psoriasis	0.000531	0.000639	CcSEcCtD
Cabergoline—Discomfort—Triamcinolone—psoriasis	0.00053	0.000639	CcSEcCtD
Cabergoline—Fatigue—Cyclosporine—psoriasis	0.00053	0.000638	CcSEcCtD
Cabergoline—Hyperhidrosis—Hydrocortisone—psoriasis	0.000528	0.000636	CcSEcCtD
Cabergoline—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000528	0.000636	CcSEcCtD
Cabergoline—Pain—Cyclosporine—psoriasis	0.000526	0.000633	CcSEcCtD
Cabergoline—Constipation—Cyclosporine—psoriasis	0.000526	0.000633	CcSEcCtD
Cabergoline—Dry mouth—Triamcinolone—psoriasis	0.000525	0.000632	CcSEcCtD
Cabergoline—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000521	0.000628	CcSEcCtD
Cabergoline—Anorexia—Hydrocortisone—psoriasis	0.000521	0.000627	CcSEcCtD
Cabergoline—Diarrhoea—Mycophenolic acid—psoriasis	0.00052	0.000626	CcSEcCtD
Cabergoline—Malaise—Dexamethasone—psoriasis	0.000516	0.000621	CcSEcCtD
Cabergoline—Malaise—Betamethasone—psoriasis	0.000516	0.000621	CcSEcCtD
Cabergoline—Oedema—Triamcinolone—psoriasis	0.000514	0.00062	CcSEcCtD
Cabergoline—Vertigo—Dexamethasone—psoriasis	0.000514	0.000619	CcSEcCtD
Cabergoline—Vertigo—Betamethasone—psoriasis	0.000514	0.000619	CcSEcCtD
Cabergoline—Syncope—Dexamethasone—psoriasis	0.000513	0.000618	CcSEcCtD
Cabergoline—Syncope—Betamethasone—psoriasis	0.000513	0.000618	CcSEcCtD
Cabergoline—Pain—Mycophenolate mofetil—psoriasis	0.000513	0.000618	CcSEcCtD
Cabergoline—Constipation—Mycophenolate mofetil—psoriasis	0.000513	0.000618	CcSEcCtD
Cabergoline—Arrhythmia—Prednisone—psoriasis	0.000511	0.000616	CcSEcCtD
Cabergoline—Hypotension—Hydrocortisone—psoriasis	0.00051	0.000615	CcSEcCtD
Cabergoline—Feeling abnormal—Cyclosporine—psoriasis	0.000506	0.00061	CcSEcCtD
Cabergoline—Shock—Triamcinolone—psoriasis	0.000506	0.00061	CcSEcCtD
Cabergoline—Insomnia—Prednisolone—psoriasis	0.000506	0.000609	CcSEcCtD
Cabergoline—Alopecia—Prednisone—psoriasis	0.000506	0.000609	CcSEcCtD
Cabergoline—Gastrointestinal pain—Cyclosporine—psoriasis	0.000503	0.000605	CcSEcCtD
Cabergoline—Loss of consciousness—Dexamethasone—psoriasis	0.000503	0.000605	CcSEcCtD
Cabergoline—Loss of consciousness—Betamethasone—psoriasis	0.000503	0.000605	CcSEcCtD
Cabergoline—Dizziness—Mycophenolic acid—psoriasis	0.000502	0.000605	CcSEcCtD
Cabergoline—Epistaxis—Methotrexate—psoriasis	0.000502	0.000605	CcSEcCtD
Cabergoline—Paraesthesia—Prednisolone—psoriasis	0.000502	0.000605	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000498	0.0006	CcSEcCtD
Cabergoline—Hyperhidrosis—Triamcinolone—psoriasis	0.000497	0.000599	CcSEcCtD
Cabergoline—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000494	0.000595	CcSEcCtD
Cabergoline—Insomnia—Hydrocortisone—psoriasis	0.000494	0.000595	CcSEcCtD
Cabergoline—Hypertension—Dexamethasone—psoriasis	0.000494	0.000595	CcSEcCtD
Cabergoline—Hypertension—Betamethasone—psoriasis	0.000494	0.000595	CcSEcCtD
Cabergoline—Paraesthesia—Hydrocortisone—psoriasis	0.00049	0.000591	CcSEcCtD
Cabergoline—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.00049	0.000591	CcSEcCtD
Cabergoline—Abdominal pain—Cyclosporine—psoriasis	0.000486	0.000585	CcSEcCtD
Cabergoline—Anxiety—Betamethasone—psoriasis	0.000485	0.000584	CcSEcCtD
Cabergoline—Anxiety—Dexamethasone—psoriasis	0.000485	0.000584	CcSEcCtD
Cabergoline—Vomiting—Mycophenolic acid—psoriasis	0.000483	0.000582	CcSEcCtD
Cabergoline—Discomfort—Dexamethasone—psoriasis	0.000481	0.000579	CcSEcCtD
Cabergoline—Discomfort—Betamethasone—psoriasis	0.000481	0.000579	CcSEcCtD
Cabergoline—Dyspepsia—Hydrocortisone—psoriasis	0.000481	0.000579	CcSEcCtD
Cabergoline—Rash—Mycophenolic acid—psoriasis	0.000479	0.000577	CcSEcCtD
Cabergoline—Dermatitis—Mycophenolic acid—psoriasis	0.000479	0.000577	CcSEcCtD
Cabergoline—Pain—Prednisolone—psoriasis	0.000478	0.000576	CcSEcCtD
Cabergoline—Headache—Mycophenolic acid—psoriasis	0.000476	0.000573	CcSEcCtD
Cabergoline—Decreased appetite—Hydrocortisone—psoriasis	0.000475	0.000572	CcSEcCtD
Cabergoline—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000474	0.000571	CcSEcCtD
Cabergoline—Fatigue—Hydrocortisone—psoriasis	0.000471	0.000567	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000469	0.000565	CcSEcCtD
Cabergoline—Pain—Hydrocortisone—psoriasis	0.000467	0.000563	CcSEcCtD
Cabergoline—Oedema—Dexamethasone—psoriasis	0.000467	0.000562	CcSEcCtD
Cabergoline—Oedema—Betamethasone—psoriasis	0.000467	0.000562	CcSEcCtD
Cabergoline—Insomnia—Triamcinolone—psoriasis	0.000465	0.00056	CcSEcCtD
Cabergoline—Ill-defined disorder—Prednisone—psoriasis	0.000462	0.000557	CcSEcCtD
Cabergoline—Paraesthesia—Triamcinolone—psoriasis	0.000462	0.000556	CcSEcCtD
Cabergoline—Feeling abnormal—Prednisolone—psoriasis	0.000461	0.000555	CcSEcCtD
Cabergoline—Visual impairment—Methotrexate—psoriasis	0.000461	0.000555	CcSEcCtD
Cabergoline—Shock—Betamethasone—psoriasis	0.000459	0.000553	CcSEcCtD
Cabergoline—Shock—Dexamethasone—psoriasis	0.000459	0.000553	CcSEcCtD
Cabergoline—Dyspnoea—Triamcinolone—psoriasis	0.000459	0.000552	CcSEcCtD
Cabergoline—Hypersensitivity—Cyclosporine—psoriasis	0.000453	0.000546	CcSEcCtD
Cabergoline—Dyspepsia—Triamcinolone—psoriasis	0.000453	0.000545	CcSEcCtD
Cabergoline—Nausea—Mycophenolic acid—psoriasis	0.000451	0.000544	CcSEcCtD
Cabergoline—Hyperhidrosis—Dexamethasone—psoriasis	0.000451	0.000543	CcSEcCtD
Cabergoline—Hyperhidrosis—Betamethasone—psoriasis	0.000451	0.000543	CcSEcCtD
Cabergoline—Feeling abnormal—Hydrocortisone—psoriasis	0.00045	0.000542	CcSEcCtD
Cabergoline—Malaise—Prednisone—psoriasis	0.000449	0.000541	CcSEcCtD
Cabergoline—Vertigo—Prednisone—psoriasis	0.000447	0.000539	CcSEcCtD
Cabergoline—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000447	0.000538	CcSEcCtD
Cabergoline—Syncope—Prednisone—psoriasis	0.000447	0.000538	CcSEcCtD
Cabergoline—Anorexia—Betamethasone—psoriasis	0.000445	0.000536	CcSEcCtD
Cabergoline—Anorexia—Dexamethasone—psoriasis	0.000445	0.000536	CcSEcCtD
Cabergoline—Cardiac disorder—Methotrexate—psoriasis	0.000444	0.000535	CcSEcCtD
Cabergoline—Fatigue—Triamcinolone—psoriasis	0.000443	0.000534	CcSEcCtD
Cabergoline—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000442	0.000532	CcSEcCtD
Cabergoline—Asthenia—Cyclosporine—psoriasis	0.000441	0.000531	CcSEcCtD
Cabergoline—Pain—Triamcinolone—psoriasis	0.00044	0.00053	CcSEcCtD
Cabergoline—Loss of consciousness—Prednisone—psoriasis	0.000438	0.000527	CcSEcCtD
Cabergoline—Hypotension—Dexamethasone—psoriasis	0.000436	0.000525	CcSEcCtD
Cabergoline—Hypotension—Betamethasone—psoriasis	0.000436	0.000525	CcSEcCtD
Cabergoline—Pruritus—Cyclosporine—psoriasis	0.000435	0.000524	CcSEcCtD
Cabergoline—Abdominal pain—Hydrocortisone—psoriasis	0.000432	0.00052	CcSEcCtD
Cabergoline—Asthenia—Mycophenolate mofetil—psoriasis	0.00043	0.000518	CcSEcCtD
Cabergoline—Hypertension—Prednisone—psoriasis	0.00043	0.000518	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000425	0.000512	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000425	0.000512	CcSEcCtD
Cabergoline—Pruritus—Mycophenolate mofetil—psoriasis	0.000424	0.000511	CcSEcCtD
Cabergoline—Arthralgia—Prednisone—psoriasis	0.000424	0.000511	CcSEcCtD
Cabergoline—Feeling abnormal—Triamcinolone—psoriasis	0.000424	0.000511	CcSEcCtD
Cabergoline—Anxiety—Prednisone—psoriasis	0.000422	0.000509	CcSEcCtD
Cabergoline—Alopecia—Methotrexate—psoriasis	0.000422	0.000509	CcSEcCtD
Cabergoline—Insomnia—Dexamethasone—psoriasis	0.000422	0.000508	CcSEcCtD
Cabergoline—Insomnia—Betamethasone—psoriasis	0.000422	0.000508	CcSEcCtD
Cabergoline—Diarrhoea—Cyclosporine—psoriasis	0.000421	0.000507	CcSEcCtD
Cabergoline—Paraesthesia—Betamethasone—psoriasis	0.000419	0.000505	CcSEcCtD
Cabergoline—Paraesthesia—Dexamethasone—psoriasis	0.000419	0.000505	CcSEcCtD
Cabergoline—Discomfort—Prednisone—psoriasis	0.000419	0.000505	CcSEcCtD
Cabergoline—Hypersensitivity—Prednisolone—psoriasis	0.000412	0.000496	CcSEcCtD
Cabergoline—Dyspepsia—Betamethasone—psoriasis	0.000411	0.000495	CcSEcCtD
Cabergoline—Dyspepsia—Dexamethasone—psoriasis	0.000411	0.000495	CcSEcCtD
Cabergoline—Diarrhoea—Mycophenolate mofetil—psoriasis	0.00041	0.000494	CcSEcCtD
Cabergoline—Dizziness—Cyclosporine—psoriasis	0.000406	0.00049	CcSEcCtD
Cabergoline—Oedema—Prednisone—psoriasis	0.000406	0.00049	CcSEcCtD
Cabergoline—Decreased appetite—Dexamethasone—psoriasis	0.000406	0.000489	CcSEcCtD
Cabergoline—Decreased appetite—Betamethasone—psoriasis	0.000406	0.000489	CcSEcCtD
Cabergoline—Back pain—Methotrexate—psoriasis	0.000403	0.000485	CcSEcCtD
Cabergoline—Hypersensitivity—Hydrocortisone—psoriasis	0.000402	0.000485	CcSEcCtD
Cabergoline—Fatigue—Betamethasone—psoriasis	0.000402	0.000485	CcSEcCtD
Cabergoline—Fatigue—Dexamethasone—psoriasis	0.000402	0.000485	CcSEcCtD
Cabergoline—Shock—Prednisone—psoriasis	0.0004	0.000482	CcSEcCtD
Cabergoline—Pain—Betamethasone—psoriasis	0.000399	0.000481	CcSEcCtD
Cabergoline—Pain—Dexamethasone—psoriasis	0.000399	0.000481	CcSEcCtD
Cabergoline—Dizziness—Mycophenolate mofetil—psoriasis	0.000396	0.000478	CcSEcCtD
Cabergoline—Hyperhidrosis—Prednisone—psoriasis	0.000393	0.000473	CcSEcCtD
Cabergoline—Asthenia—Hydrocortisone—psoriasis	0.000392	0.000472	CcSEcCtD
Cabergoline—Vomiting—Cyclosporine—psoriasis	0.000391	0.000471	CcSEcCtD
Cabergoline—Rash—Cyclosporine—psoriasis	0.000388	0.000467	CcSEcCtD
Cabergoline—Anorexia—Prednisone—psoriasis	0.000387	0.000467	CcSEcCtD
Cabergoline—Dermatitis—Cyclosporine—psoriasis	0.000387	0.000466	CcSEcCtD
Cabergoline—Pruritus—Hydrocortisone—psoriasis	0.000386	0.000466	CcSEcCtD
Cabergoline—Ill-defined disorder—Methotrexate—psoriasis	0.000386	0.000465	CcSEcCtD
Cabergoline—Headache—Cyclosporine—psoriasis	0.000385	0.000464	CcSEcCtD
Cabergoline—Feeling abnormal—Dexamethasone—psoriasis	0.000385	0.000463	CcSEcCtD
Cabergoline—Feeling abnormal—Betamethasone—psoriasis	0.000385	0.000463	CcSEcCtD
Cabergoline—Gastrointestinal pain—Dexamethasone—psoriasis	0.000382	0.00046	CcSEcCtD
Cabergoline—Gastrointestinal pain—Betamethasone—psoriasis	0.000382	0.00046	CcSEcCtD
Cabergoline—Vomiting—Mycophenolate mofetil—psoriasis	0.000381	0.000459	CcSEcCtD
Cabergoline—Hypersensitivity—Triamcinolone—psoriasis	0.000379	0.000457	CcSEcCtD
Cabergoline—Rash—Mycophenolate mofetil—psoriasis	0.000378	0.000455	CcSEcCtD
Cabergoline—Dermatitis—Mycophenolate mofetil—psoriasis	0.000378	0.000455	CcSEcCtD
Cabergoline—Headache—Mycophenolate mofetil—psoriasis	0.000376	0.000452	CcSEcCtD
Cabergoline—Malaise—Methotrexate—psoriasis	0.000375	0.000452	CcSEcCtD
Cabergoline—Vertigo—Methotrexate—psoriasis	0.000374	0.00045	CcSEcCtD
Cabergoline—Diarrhoea—Hydrocortisone—psoriasis	0.000374	0.00045	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Prednisone—psoriasis	0.00037	0.000446	CcSEcCtD
Cabergoline—Dizziness—Prednisolone—psoriasis	0.00037	0.000446	CcSEcCtD
Cabergoline—Asthenia—Triamcinolone—psoriasis	0.000369	0.000445	CcSEcCtD
Cabergoline—Abdominal pain—Betamethasone—psoriasis	0.000369	0.000444	CcSEcCtD
Cabergoline—Abdominal pain—Dexamethasone—psoriasis	0.000369	0.000444	CcSEcCtD
Cabergoline—Insomnia—Prednisone—psoriasis	0.000368	0.000443	CcSEcCtD
Cabergoline—Nausea—Cyclosporine—psoriasis	0.000365	0.00044	CcSEcCtD
Cabergoline—Paraesthesia—Prednisone—psoriasis	0.000365	0.00044	CcSEcCtD
Cabergoline—Pruritus—Triamcinolone—psoriasis	0.000364	0.000438	CcSEcCtD
Cabergoline—Dizziness—Hydrocortisone—psoriasis	0.000361	0.000435	CcSEcCtD
Cabergoline—Dyspepsia—Prednisone—psoriasis	0.000358	0.000431	CcSEcCtD
Cabergoline—Nausea—Mycophenolate mofetil—psoriasis	0.000356	0.000429	CcSEcCtD
Cabergoline—Arthralgia—Methotrexate—psoriasis	0.000354	0.000427	CcSEcCtD
Cabergoline—Decreased appetite—Prednisone—psoriasis	0.000353	0.000426	CcSEcCtD
Cabergoline—Rash—Prednisolone—psoriasis	0.000353	0.000425	CcSEcCtD
Cabergoline—Dermatitis—Prednisolone—psoriasis	0.000352	0.000424	CcSEcCtD
Cabergoline—Fatigue—Prednisone—psoriasis	0.00035	0.000422	CcSEcCtD
Cabergoline—Headache—Prednisolone—psoriasis	0.00035	0.000422	CcSEcCtD
Cabergoline—Discomfort—Methotrexate—psoriasis	0.00035	0.000422	CcSEcCtD
Cabergoline—Constipation—Prednisone—psoriasis	0.000348	0.000419	CcSEcCtD
Cabergoline—Vomiting—Hydrocortisone—psoriasis	0.000347	0.000418	CcSEcCtD
Cabergoline—Rash—Hydrocortisone—psoriasis	0.000344	0.000415	CcSEcCtD
Cabergoline—Dermatitis—Hydrocortisone—psoriasis	0.000344	0.000415	CcSEcCtD
Cabergoline—Confusional state—Methotrexate—psoriasis	0.000342	0.000413	CcSEcCtD
Cabergoline—Headache—Hydrocortisone—psoriasis	0.000342	0.000412	CcSEcCtD
Cabergoline—Dizziness—Triamcinolone—psoriasis	0.00034	0.00041	CcSEcCtD
Cabergoline—Feeling abnormal—Prednisone—psoriasis	0.000335	0.000403	CcSEcCtD
Cabergoline—Asthenia—Dexamethasone—psoriasis	0.000335	0.000403	CcSEcCtD
Cabergoline—Asthenia—Betamethasone—psoriasis	0.000335	0.000403	CcSEcCtD
Cabergoline—Gastrointestinal pain—Prednisone—psoriasis	0.000332	0.0004	CcSEcCtD
Cabergoline—Nausea—Prednisolone—psoriasis	0.000332	0.0004	CcSEcCtD
Cabergoline—Pruritus—Dexamethasone—psoriasis	0.00033	0.000398	CcSEcCtD
Cabergoline—Pruritus—Betamethasone—psoriasis	0.00033	0.000398	CcSEcCtD
Cabergoline—Hyperhidrosis—Methotrexate—psoriasis	0.000328	0.000396	CcSEcCtD
Cabergoline—Vomiting—Triamcinolone—psoriasis	0.000327	0.000394	CcSEcCtD
Cabergoline—Nausea—Hydrocortisone—psoriasis	0.000324	0.000391	CcSEcCtD
Cabergoline—Rash—Triamcinolone—psoriasis	0.000324	0.000391	CcSEcCtD
Cabergoline—Dermatitis—Triamcinolone—psoriasis	0.000324	0.00039	CcSEcCtD
Cabergoline—Anorexia—Methotrexate—psoriasis	0.000324	0.00039	CcSEcCtD
Cabergoline—Headache—Triamcinolone—psoriasis	0.000322	0.000388	CcSEcCtD
Cabergoline—Abdominal pain—Prednisone—psoriasis	0.000321	0.000387	CcSEcCtD
Cabergoline—Diarrhoea—Dexamethasone—psoriasis	0.000319	0.000385	CcSEcCtD
Cabergoline—Diarrhoea—Betamethasone—psoriasis	0.000319	0.000385	CcSEcCtD
Cabergoline—Hypotension—Methotrexate—psoriasis	0.000317	0.000382	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000309	0.000373	CcSEcCtD
Cabergoline—Dizziness—Betamethasone—psoriasis	0.000309	0.000372	CcSEcCtD
Cabergoline—Dizziness—Dexamethasone—psoriasis	0.000309	0.000372	CcSEcCtD
Cabergoline—Insomnia—Methotrexate—psoriasis	0.000307	0.00037	CcSEcCtD
Cabergoline—Nausea—Triamcinolone—psoriasis	0.000306	0.000368	CcSEcCtD
Cabergoline—Paraesthesia—Methotrexate—psoriasis	0.000305	0.000367	CcSEcCtD
Cabergoline—Dyspnoea—Methotrexate—psoriasis	0.000303	0.000365	CcSEcCtD
Cabergoline—Somnolence—Methotrexate—psoriasis	0.000302	0.000364	CcSEcCtD
Cabergoline—Hypersensitivity—Prednisone—psoriasis	0.000299	0.000361	CcSEcCtD
Cabergoline—Dyspepsia—Methotrexate—psoriasis	0.000299	0.00036	CcSEcCtD
Cabergoline—Vomiting—Dexamethasone—psoriasis	0.000297	0.000357	CcSEcCtD
Cabergoline—Vomiting—Betamethasone—psoriasis	0.000297	0.000357	CcSEcCtD
Cabergoline—Decreased appetite—Methotrexate—psoriasis	0.000295	0.000356	CcSEcCtD
Cabergoline—Rash—Betamethasone—psoriasis	0.000294	0.000354	CcSEcCtD
Cabergoline—Rash—Dexamethasone—psoriasis	0.000294	0.000354	CcSEcCtD
Cabergoline—Dermatitis—Betamethasone—psoriasis	0.000294	0.000354	CcSEcCtD
Cabergoline—Dermatitis—Dexamethasone—psoriasis	0.000294	0.000354	CcSEcCtD
Cabergoline—Fatigue—Methotrexate—psoriasis	0.000293	0.000353	CcSEcCtD
Cabergoline—Headache—Betamethasone—psoriasis	0.000292	0.000352	CcSEcCtD
Cabergoline—Headache—Dexamethasone—psoriasis	0.000292	0.000352	CcSEcCtD
Cabergoline—Asthenia—Prednisone—psoriasis	0.000292	0.000351	CcSEcCtD
Cabergoline—Pain—Methotrexate—psoriasis	0.00029	0.00035	CcSEcCtD
Cabergoline—Pruritus—Prednisone—psoriasis	0.000288	0.000346	CcSEcCtD
Cabergoline—Feeling abnormal—Methotrexate—psoriasis	0.00028	0.000337	CcSEcCtD
Cabergoline—Diarrhoea—Prednisone—psoriasis	0.000278	0.000335	CcSEcCtD
Cabergoline—Gastrointestinal pain—Methotrexate—psoriasis	0.000278	0.000335	CcSEcCtD
Cabergoline—Nausea—Dexamethasone—psoriasis	0.000277	0.000334	CcSEcCtD
Cabergoline—Nausea—Betamethasone—psoriasis	0.000277	0.000334	CcSEcCtD
Cabergoline—Dizziness—Prednisone—psoriasis	0.000269	0.000324	CcSEcCtD
Cabergoline—Abdominal pain—Methotrexate—psoriasis	0.000269	0.000323	CcSEcCtD
Cabergoline—Vomiting—Prednisone—psoriasis	0.000258	0.000311	CcSEcCtD
Cabergoline—Rash—Prednisone—psoriasis	0.000256	0.000309	CcSEcCtD
Cabergoline—Dermatitis—Prednisone—psoriasis	0.000256	0.000308	CcSEcCtD
Cabergoline—Headache—Prednisone—psoriasis	0.000255	0.000307	CcSEcCtD
Cabergoline—Hypersensitivity—Methotrexate—psoriasis	0.00025	0.000301	CcSEcCtD
Cabergoline—Asthenia—Methotrexate—psoriasis	0.000244	0.000294	CcSEcCtD
Cabergoline—Nausea—Prednisone—psoriasis	0.000241	0.000291	CcSEcCtD
Cabergoline—Pruritus—Methotrexate—psoriasis	0.00024	0.000289	CcSEcCtD
Cabergoline—Diarrhoea—Methotrexate—psoriasis	0.000232	0.00028	CcSEcCtD
Cabergoline—Dizziness—Methotrexate—psoriasis	0.000225	0.000271	CcSEcCtD
Cabergoline—Vomiting—Methotrexate—psoriasis	0.000216	0.00026	CcSEcCtD
Cabergoline—Rash—Methotrexate—psoriasis	0.000214	0.000258	CcSEcCtD
Cabergoline—Dermatitis—Methotrexate—psoriasis	0.000214	0.000258	CcSEcCtD
Cabergoline—Headache—Methotrexate—psoriasis	0.000213	0.000256	CcSEcCtD
Cabergoline—Nausea—Methotrexate—psoriasis	0.000202	0.000243	CcSEcCtD
Cabergoline—DRD5—Signaling Pathways—CXCL8—psoriasis	1.94e-05	0.000304	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—APOE—psoriasis	1.94e-05	0.000304	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—LEP—psoriasis	1.94e-05	0.000304	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—APOE—psoriasis	1.93e-05	0.000302	CbGpPWpGaD
Cabergoline—ADRB2—Signaling by GPCR—CXCL8—psoriasis	1.92e-05	0.0003	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—NFKBIA—psoriasis	1.92e-05	0.0003	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—APOE—psoriasis	1.92e-05	0.0003	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—LEP—psoriasis	1.92e-05	0.0003	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—LEP—psoriasis	1.92e-05	0.0003	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—APOE—psoriasis	1.92e-05	0.0003	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—SOCS1—psoriasis	1.92e-05	0.000299	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—TYK2—psoriasis	1.9e-05	0.000296	CbGpPWpGaD
Cabergoline—HTR1A—Signaling by GPCR—CXCL8—psoriasis	1.88e-05	0.000294	CbGpPWpGaD
Cabergoline—HTR2C—Signaling by GPCR—CXCL8—psoriasis	1.87e-05	0.000292	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—TYK2—psoriasis	1.87e-05	0.000291	CbGpPWpGaD
Cabergoline—DRD5—Signaling by GPCR—IL6—psoriasis	1.85e-05	0.000289	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—TYK2—psoriasis	1.83e-05	0.000285	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling by GPCR—CXCL8—psoriasis	1.82e-05	0.000284	CbGpPWpGaD
Cabergoline—DRD2—GPCR downstream signaling—CXCL8—psoriasis	1.82e-05	0.000284	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—NFKBIA—psoriasis	1.81e-05	0.000283	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—JUN—psoriasis	1.81e-05	0.000282	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—CXCL8—psoriasis	1.79e-05	0.00028	CbGpPWpGaD
Cabergoline—HTR2A—GPCR downstream signaling—CXCL8—psoriasis	1.79e-05	0.000279	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—NFKBIA—psoriasis	1.79e-05	0.000279	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—NFKBIA—psoriasis	1.79e-05	0.000279	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—SOCS1—psoriasis	1.78e-05	0.000278	CbGpPWpGaD
Cabergoline—ADRA1A—GPCR downstream signaling—CXCL8—psoriasis	1.75e-05	0.000274	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—APOE—psoriasis	1.75e-05	0.000273	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—LEP—psoriasis	1.75e-05	0.000273	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—NFKB1—psoriasis	1.74e-05	0.000272	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—LEP—psoriasis	1.73e-05	0.00027	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—APOE—psoriasis	1.73e-05	0.00027	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—TYK2—psoriasis	1.72e-05	0.000269	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—TYK2—psoriasis	1.71e-05	0.000267	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—LEP—psoriasis	1.71e-05	0.000267	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—APOE—psoriasis	1.71e-05	0.000267	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—TYK2—psoriasis	1.7e-05	0.000265	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—PPARG—psoriasis	1.68e-05	0.000263	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—TYK2—psoriasis	1.67e-05	0.000262	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—APOE—psoriasis	1.67e-05	0.000261	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—LEP—psoriasis	1.67e-05	0.000261	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—LEP—psoriasis	1.66e-05	0.00026	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—APOE—psoriasis	1.66e-05	0.00026	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—CXCL8—psoriasis	1.65e-05	0.000258	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—TYK2—psoriasis	1.65e-05	0.000257	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—NFKBIA—psoriasis	1.63e-05	0.000254	CbGpPWpGaD
Cabergoline—ADRA2A—GPCR downstream signaling—CXCL8—psoriasis	1.63e-05	0.000254	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—CXCL8—psoriasis	1.62e-05	0.000254	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—LEP—psoriasis	1.62e-05	0.000253	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—APOE—psoriasis	1.62e-05	0.000253	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—NFKBIA—psoriasis	1.61e-05	0.000252	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—NFKBIA—psoriasis	1.59e-05	0.000249	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—LEP—psoriasis	1.59e-05	0.000249	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—APOE—psoriasis	1.59e-05	0.000249	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—CXCL8—psoriasis	1.59e-05	0.000248	CbGpPWpGaD
Cabergoline—ADRA2A—Hemostasis—TP53—psoriasis	1.58e-05	0.000247	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—VEGFA—psoriasis	1.58e-05	0.000247	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—TYK2—psoriasis	1.57e-05	0.000246	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—APOE—psoriasis	1.57e-05	0.000245	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—STAT3—psoriasis	1.56e-05	0.000244	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—NFKBIA—psoriasis	1.56e-05	0.000243	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—NFKBIA—psoriasis	1.55e-05	0.000242	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—NFKBIA—psoriasis	1.51e-05	0.000235	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—CXCL8—psoriasis	1.5e-05	0.000234	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—CXCL8—psoriasis	1.49e-05	0.000233	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—TYK2—psoriasis	1.48e-05	0.000232	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—NFKBIA—psoriasis	1.48e-05	0.000232	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—CXCL8—psoriasis	1.48e-05	0.000231	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—APOE—psoriasis	1.47e-05	0.000229	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—LEP—psoriasis	1.47e-05	0.000229	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—TYK2—psoriasis	1.46e-05	0.000229	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—TYK2—psoriasis	1.46e-05	0.000229	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—CXCL8—psoriasis	1.46e-05	0.000228	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—APOE—psoriasis	1.44e-05	0.000226	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—LEP—psoriasis	1.44e-05	0.000226	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—CXCL8—psoriasis	1.43e-05	0.000224	CbGpPWpGaD
Cabergoline—HTR7—Signaling by GPCR—IL6—psoriasis	1.43e-05	0.000223	CbGpPWpGaD
Cabergoline—HTR1D—Signaling by GPCR—IL6—psoriasis	1.42e-05	0.000221	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—APOE—psoriasis	1.41e-05	0.000221	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—LEP—psoriasis	1.41e-05	0.000221	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CARM1—psoriasis	1.4e-05	0.000219	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—JUN—psoriasis	1.39e-05	0.000218	CbGpPWpGaD
Cabergoline—HTR1B—Signaling by GPCR—IL6—psoriasis	1.39e-05	0.000217	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—JUN—psoriasis	1.38e-05	0.000216	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—CXCL8—psoriasis	1.37e-05	0.000214	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PPARG—psoriasis	1.37e-05	0.000214	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—NFKBIA—psoriasis	1.37e-05	0.000214	CbGpPWpGaD
Cabergoline—DRD4—Signaling by GPCR—IL6—psoriasis	1.36e-05	0.000213	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—JUN—psoriasis	1.36e-05	0.000212	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—NFKBIA—psoriasis	1.35e-05	0.00021	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—NFKB1—psoriasis	1.34e-05	0.000209	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—JUN—psoriasis	1.33e-05	0.000208	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TYK2—psoriasis	1.33e-05	0.000208	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—NFKB1—psoriasis	1.33e-05	0.000208	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TYK2—psoriasis	1.32e-05	0.000206	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—NFKBIA—psoriasis	1.32e-05	0.000206	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—APOE—psoriasis	1.31e-05	0.000205	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—LEP—psoriasis	1.31e-05	0.000205	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—NFKB1—psoriasis	1.3e-05	0.000204	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TYK2—psoriasis	1.3e-05	0.000204	CbGpPWpGaD
Cabergoline—HTR2B—Signaling by GPCR—IL6—psoriasis	1.3e-05	0.000203	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—CXCL8—psoriasis	1.29e-05	0.000202	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—NFKB1—psoriasis	1.28e-05	0.000201	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TYK2—psoriasis	1.28e-05	0.000199	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—CXCL8—psoriasis	1.27e-05	0.000199	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—CXCL8—psoriasis	1.27e-05	0.000199	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—JUN—psoriasis	1.27e-05	0.000199	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TYK2—psoriasis	1.27e-05	0.000198	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TYK2—psoriasis	1.23e-05	0.000193	CbGpPWpGaD
Cabergoline—DRD1—Signaling by GPCR—IL6—psoriasis	1.23e-05	0.000192	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—NFKB1—psoriasis	1.23e-05	0.000191	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—NFKBIA—psoriasis	1.22e-05	0.000191	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—VEGFA—psoriasis	1.22e-05	0.00019	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TYK2—psoriasis	1.21e-05	0.00019	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling by GPCR—IL6—psoriasis	1.21e-05	0.000189	CbGpPWpGaD
Cabergoline—DRD3—Signaling by GPCR—IL6—psoriasis	1.21e-05	0.000189	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—VEGFA—psoriasis	1.21e-05	0.000189	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—STAT3—psoriasis	1.21e-05	0.000188	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—JUN—psoriasis	1.2e-05	0.000188	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—STAT3—psoriasis	1.2e-05	0.000187	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—TP53—psoriasis	1.19e-05	0.000186	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—JUN—psoriasis	1.18e-05	0.000185	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—JUN—psoriasis	1.18e-05	0.000185	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—VEGFA—psoriasis	1.18e-05	0.000185	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—STAT3—psoriasis	1.17e-05	0.000183	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—VEGFA—psoriasis	1.17e-05	0.000182	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—CXCL8—psoriasis	1.16e-05	0.000181	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—NFKB1—psoriasis	1.16e-05	0.000181	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—STAT3—psoriasis	1.15e-05	0.00018	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—CXCL8—psoriasis	1.15e-05	0.00018	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—NFKB1—psoriasis	1.14e-05	0.000178	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—NFKB1—psoriasis	1.14e-05	0.000178	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—CXCL8—psoriasis	1.14e-05	0.000177	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TYK2—psoriasis	1.12e-05	0.000175	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—VEGFA—psoriasis	1.11e-05	0.000174	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—CXCL8—psoriasis	1.11e-05	0.000173	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—CXCL8—psoriasis	1.1e-05	0.000173	CbGpPWpGaD
Cabergoline—ADRB1—Signaling by GPCR—IL6—psoriasis	1.1e-05	0.000172	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TYK2—psoriasis	1.1e-05	0.000172	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—STAT3—psoriasis	1.1e-05	0.000172	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling by GPCR—IL6—psoriasis	1.09e-05	0.000171	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—IL6—psoriasis	1.09e-05	0.000171	CbGpPWpGaD
Cabergoline—ADRB2—Signaling by GPCR—IL6—psoriasis	1.08e-05	0.000169	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—JUN—psoriasis	1.08e-05	0.000169	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TYK2—psoriasis	1.08e-05	0.000169	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—CXCL8—psoriasis	1.07e-05	0.000168	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—JUN—psoriasis	1.07e-05	0.000167	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—CXCL8—psoriasis	1.06e-05	0.000165	CbGpPWpGaD
Cabergoline—HTR1A—Signaling by GPCR—IL6—psoriasis	1.06e-05	0.000165	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—JUN—psoriasis	1.06e-05	0.000165	CbGpPWpGaD
Cabergoline—HTR2C—Signaling by GPCR—IL6—psoriasis	1.05e-05	0.000164	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—VEGFA—psoriasis	1.05e-05	0.000164	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—NFKB1—psoriasis	1.04e-05	0.000162	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—STAT3—psoriasis	1.04e-05	0.000162	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—VEGFA—psoriasis	1.03e-05	0.000162	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—VEGFA—psoriasis	1.03e-05	0.000162	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—JUN—psoriasis	1.03e-05	0.000161	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—NFKB1—psoriasis	1.03e-05	0.000161	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—JUN—psoriasis	1.03e-05	0.00016	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—STAT3—psoriasis	1.02e-05	0.00016	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—STAT3—psoriasis	1.02e-05	0.00016	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling by GPCR—IL6—psoriasis	1.02e-05	0.00016	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—NFKB1—psoriasis	1.02e-05	0.000159	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—IL6—psoriasis	1.01e-05	0.000157	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TYK2—psoriasis	1e-05	0.000157	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—JUN—psoriasis	9.99e-06	0.000156	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—NFKB1—psoriasis	9.94e-06	0.000155	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—NFKB1—psoriasis	9.89e-06	0.000154	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—JUN—psoriasis	9.83e-06	0.000154	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CXCL8—psoriasis	9.75e-06	0.000152	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—NFKB1—psoriasis	9.62e-06	0.00015	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CXCL8—psoriasis	9.59e-06	0.00015	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—NFKB1—psoriasis	9.46e-06	0.000148	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—VEGFA—psoriasis	9.43e-06	0.000147	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CXCL8—psoriasis	9.39e-06	0.000147	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—VEGFA—psoriasis	9.34e-06	0.000146	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—STAT3—psoriasis	9.34e-06	0.000146	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—IL6—psoriasis	9.27e-06	0.000145	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—STAT3—psoriasis	9.25e-06	0.000145	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—VEGFA—psoriasis	9.22e-06	0.000144	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—TP53—psoriasis	9.2e-06	0.000144	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—TP53—psoriasis	9.14e-06	0.000143	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—STAT3—psoriasis	9.13e-06	0.000143	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—IL6—psoriasis	9.12e-06	0.000142	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—JUN—psoriasis	9.06e-06	0.000142	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—VEGFA—psoriasis	9.02e-06	0.000141	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—VEGFA—psoriasis	8.97e-06	0.00014	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—TP53—psoriasis	8.95e-06	0.00014	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—IL6—psoriasis	8.93e-06	0.00014	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—STAT3—psoriasis	8.93e-06	0.000139	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—JUN—psoriasis	8.92e-06	0.000139	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—STAT3—psoriasis	8.89e-06	0.000139	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—TP53—psoriasis	8.8e-06	0.000138	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—JUN—psoriasis	8.73e-06	0.000136	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CXCL8—psoriasis	8.73e-06	0.000136	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—VEGFA—psoriasis	8.73e-06	0.000136	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—NFKB1—psoriasis	8.73e-06	0.000136	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—STAT3—psoriasis	8.64e-06	0.000135	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CAT—psoriasis	8.61e-06	0.000135	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—VEGFA—psoriasis	8.59e-06	0.000134	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—NFKB1—psoriasis	8.59e-06	0.000134	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—STAT3—psoriasis	8.51e-06	0.000133	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—IL6—psoriasis	8.42e-06	0.000131	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—NFKB1—psoriasis	8.41e-06	0.000131	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—TP53—psoriasis	8.4e-06	0.000131	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—IL6—psoriasis	8.36e-06	0.000131	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—IL6—psoriasis	8.3e-06	0.00013	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—IL6—psoriasis	8.19e-06	0.000128	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—JUN—psoriasis	8.11e-06	0.000127	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—IL6—psoriasis	8.06e-06	0.000126	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—TP53—psoriasis	7.93e-06	0.000124	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—VEGFA—psoriasis	7.92e-06	0.000124	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—STAT3—psoriasis	7.84e-06	0.000122	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—TP53—psoriasis	7.82e-06	0.000122	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—TP53—psoriasis	7.82e-06	0.000122	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—NFKB1—psoriasis	7.81e-06	0.000122	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—VEGFA—psoriasis	7.79e-06	0.000122	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—STAT3—psoriasis	7.72e-06	0.000121	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—IL6—psoriasis	7.69e-06	0.00012	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—VEGFA—psoriasis	7.63e-06	0.000119	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—STAT3—psoriasis	7.55e-06	0.000118	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—IL6—psoriasis	7.25e-06	0.000113	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—IL6—psoriasis	7.16e-06	0.000112	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—IL6—psoriasis	7.16e-06	0.000112	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TP53—psoriasis	7.13e-06	0.000111	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—VEGFA—psoriasis	7.09e-06	0.000111	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TP53—psoriasis	7.06e-06	0.00011	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—STAT3—psoriasis	7.02e-06	0.00011	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TP53—psoriasis	6.97e-06	0.000109	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TP53—psoriasis	6.82e-06	0.000106	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TP53—psoriasis	6.78e-06	0.000106	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—APOE—psoriasis	6.69e-06	0.000105	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TP53—psoriasis	6.59e-06	0.000103	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—IL6—psoriasis	6.52e-06	0.000102	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TP53—psoriasis	6.49e-06	0.000101	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—IL6—psoriasis	6.46e-06	0.000101	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—IL6—psoriasis	6.38e-06	9.97e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—IL6—psoriasis	6.24e-06	9.74e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—IL6—psoriasis	6.21e-06	9.69e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—IL6—psoriasis	6.04e-06	9.43e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TP53—psoriasis	5.98e-06	9.35e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—IL6—psoriasis	5.94e-06	9.28e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TP53—psoriasis	5.89e-06	9.2e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PPARG—psoriasis	5.83e-06	9.1e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TP53—psoriasis	5.77e-06	9e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—IL6—psoriasis	5.48e-06	8.56e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL6—psoriasis	5.39e-06	8.42e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TP53—psoriasis	5.36e-06	8.37e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL6—psoriasis	5.28e-06	8.24e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL6—psoriasis	4.9e-06	7.66e-05	CbGpPWpGaD
